effect of drugs presentation

Got any suggestions?

We want to hear from you! Send us a message and help improve Slidesgo

Top searches

Trending searches

11 templates

20 templates

holy spirit

36 templates

9 templates

25 templates

memorial day

12 templates

Drug Effects Breakthrough

It seems that you like this template, drug effects breakthrough presentation, premium google slides theme and powerpoint template.

Do you need to explain your research and all the new information that you’re ready to provide to the community? To give an engaging presentation about a medical breakthrough, this new free template is tailor-made for you.

Slidesgo can help you with the process, and thus we’ve opted for a catchy and creative presentation. For example, you’ll find flat-styled illustrations over a solid yellow background, which inspires some energy and enthusiasm. The graphic resources included have a colored linear style, which is more than enough to grab attention. Typography contributes to the readability. Since statistical and numeric data is key here, make use of our graphs, tables and infographics to help everybody understand your point. As with all our presentation templates and themes, everything is customizable, so, even though in this case we have illustrated a drug-effect topic, you can adapt the decks to your needs. Our final slides contain many resources that you can use, and if that’s not enough, you can access Freepik or Flaticon to find what you’re looking for!

Features of this template

• 100% editable and easy to modify
• 18 different slides to impress your audience
• Contains easy-to-edit graphics and maps
• Includes 1000+ icons and Flaticon's extension for customizing your slides
• Designed to be used in Google Slides and Microsoft PowerPoint
• 16:9 widescreen format suitable for all types of screens
• Includes information about fonts, colors, and credits of the free resources used

What are the benefits of having a Premium account?

What Premium plans do you have?

What can I do to have unlimited downloads?

Don’t want to attribute Slidesgo?

Gain access to over 24200 templates & presentations with premium from 1.67€/month.

Are you already Premium? Log in

Related posts on our blog

How to Add, Duplicate, Move, Delete or Hide Slides in Google Slides

How to Change Layouts in PowerPoint

How to Change the Slide Size in Google Slides

Related presentations.

Premium template

Unlock this template and gain unlimited access

Researched by Consultants from Top-Tier Management Companies

Powerpoint Templates

Icon Bundle

Kpi Dashboard

Professional

Business Plans

Swot Analysis

Gantt Chart

Business Proposal

Marketing Plan

Project Management

Business Case

Business Model

Cyber Security

Business PPT

Digital Marketing

Digital Transformation

Human Resources

Product Management

Artificial Intelligence

Company Profile

Acknowledgement PPT

PPT Presentation

Reports Brochures

One Page Pitch

Interview PPT

All Categories

Top 10 Drugs PowerPoint Templates with Examples and Samples

Gunjan Gupta

Gabor Maté, a renowned addiction expert, once said: "Not all addictions come from abuse or trauma, but I believe they all stem from painful experiences. Hurt is at the core of all addictive behaviors." This viewpoint encourages us to see drug-use not just as a problem or a moral failing, but as a human struggle, echoing the pain and challenges many face. In the heart of every person battling addiction lies a story not just of despair but also a cry for help with a potential of healing.

For example, let’s take the story of Emma–a bright university student, whose initial drug use spiraled into a profound addiction. Transitioning from a well laid out life on campus to one on the streets, Emma faced immense emotional turmoil, societal stigma, and severe judgment for her addiction. 

And this is what our pharmaceutical industry is trying to eradicate by developing new and useful drugs to help save our youngsters each passing day. However, this process isn’t as easy as it sounds!

Thus, as a responsible scientist in charge of a pharmaceutical drug development process, it's crucial to arm yourself with the correct knowledge and tools. Ready-made PowerPoint Templates can be invaluable in this regard. Our drugs PowerPoint Templates offer a structured way to present information on drug awareness, prevention strategies, and recovery stories, helping to engage audiences, share knowledge, and spark action.

Are you worried about substance abuse in your workplace or school, and how can you address them effectively? Here is a blog with ready-to-use templates to do so with ease!

By weaving real-life stories with accessible resources, you can promote a more empathetic, informed, and proactive approach to drug challenges. 

Need to present complex medical information in a clear and concise way? This post and templates can be your secret weapon! 

Let’s begin now and explore the ten most-downloaded drugs PowerPoint Templates from our library of over 5 million presentation designs! 

Template 1: New Drug Development Process PowerPoint Presentation

Delve into the journey of introducing a new medicine to your local pharmacy with this enlightening PowerPoint Presentation. Explore the intricate steps involved, from the initial spark of an idea to its arrival on the market shelves. This PPT Template walks you through the essential phases like early research, animal testing, human trials, regulatory green lights, and the grand unveiling to the public. It also sheds light on clinical trials with goals such as testing if the drug has any effect, expanding drug administration, performing comparative analysis, and more. Tailored for pharmaceutical wizards, curious researchers, and savvy educators, it unpacks the scientific marvels, ethical dilemmas, and business savvy behind every pill we swallow. Grab this PPT Layout now!

Download now 

Template 2: Drug Discovery and Development Clinical Research

Explore the exciting journey of creating a new medicine with this PPT design. The PPT Slide will take you step by step through developing a drug, from the beginning, such as drug discovery, preclinical development, clinical research, etc, to monitoring it once it is available. Also, learn about other important information, like adjusting the formula, ensuring safety, and getting approval. It's all about understanding how each part is vital in ensuring the medicine works well and succeeds. So, whether you're a curious scientist, a pharmaceutical company, or someone with a keen interest, this presentation template is for you. Get it now from the link below.

Template 3: Drug Indication Expansion in a Pharma Company Case Competition Complete Deck

Looking to broaden the reach of your pharmaceutical products? Dive into our Drug Indication Expansion in a Pharma Company case competition deck. This comprehensive presentation is specifically for pharma companies, strategists, and business development pros eager to explore new therapeutic avenues. Learn how to expand the usage of your existing drugs into fresh markets, boosting profitability and extending their lifecycle. It covers everything from market analysis and regulatory hurdles to designing effective clinical trials and crafting solid commercial strategies with slides like company overview, current issue and solution, SWOT analysis, product development strategy, pricing strategy, and more. Discover how to identify and validate new use cases, giving your drugs the potential to make an even bigger impact on patients' lives while growing your business using this PowerPoint Presentation. Download now!

Download now  

Template 4: Phases of Drug Discovery and Development Process PowerPoint Presentation

Present a roadmap for making new medicines with this PPT design. It is easy to understand PPT Guide for teachers, scientists, and people in the drug industry. The slides cover everything from finding the first idea for a medicine to watching how well it works after it's for sale. Each step is important, like checking the idea, finding good chemicals, testing them in labs, and trying them on people. It also includes reasons for drug failure on the basis of toxicity, efficacy, inadequate drug performance, and more. Additionally, it shows the challenges and successes of making a new medicine, giving a full view of how it's done. It's like a behind-the-scenes look at the complicated process of making medicines. Download it now! 

Template 5: Quality by Design for Generic Drugs PowerPoint Presentation

Shed light on substance misuse and the paramount importance of responsible medication management. This PPT Presentation is crafted to cater to healthcare professionals, educators, and individuals dedicated to raising awareness about. It explores a wide spectrum of topics, spanning from pharmaceutical development overview, general information such as API, registration status, applications, process parameters, identifying indicators of misuse to instituting safe medication protocols, etc. Through comprehensive education and community engagement, its endeavor is to confront substance abuse head-on, fostering a healthier and safer environment for all. Download it now from the link below!

Template 6: Drug Abuse Awareness Medicinal Measuring Individual Spreading

Looking out for our community's well-being is essential, so we created this Drug Abuse Awareness: Medicinal Measuring & Individual Spreading presentation. It allows you to talk about how drugs can be harmful and why it's important to use medication correctly. This PPT Presentation is great for doctors, teachers, and anyone who cares about spreading the word. It can be used to spot signs of drug problems with various icons and imagery such as drug abuse posters, drug abuse quotes, drug abuse slogans, and more. By teaching ourselves and others, we can take on drug abuse and make our communities healthier and safer. This presentation isn't just full of facts—it's a big help in our mission to be healthier and happier. So download it now! 

Template 7: Blockchain Technology Impact on Drugs Supply Chain Domain Training PPT

Detail the multifaceted issues addressed by integrating blockchain into drug and medical device supply chains. It lays out the benefits, such as reduction in complexity, costs, and errors, and the enhancement of security and transparency. The emphasis on shared, trusted transactions and the creation of an audit trail highlights blockchain's potential to improve efficiency and reliability in the supply chain. This PPT Design is an influential tool for convincing decision-makers of the need to adopt blockchain for operational improvements and to maintain the integrity of pharmaceutical products. Click on the link below to get it now!

Template 8: Pharma Drugs Supply Chain Distribution Flowchart

Lay down the step by step guide showing how drugs move through the system with this PPT Slide. Highlight the important people and organizations involved, such as the Food and Drug Administration, developers, distributors, and the pharmacies where you pick them up using this PPT slide. This makes it easier for everyone to understand how drugs are developed, checked for safety, and sent out to patients, helping everyone involved see what they need to do and how they fit into the process. As an essential educational resource, this PPT Slide is indispensable for training purposes, particularly in the areas of logistics within the realm of the pharmaceutical sector. Grab it now! 

Template 9: Blockchain Impact On Drugs Supply Chain With Enhanced Transparency Between Authorized Parties Training PPT

Inform stakeholders about the transformative potential of blockchain technology in managing the drug supply chain with this PPT Design. Explain the need for transparency within the supply chain to combat the prevalence of counterfeit medications. Also bring attention to the crucial function of pharmacy inspectors and the active involvement of all parties, demonstrating how blockchain technology can deliver a clear and accountable record for every transaction made with this PPT Slide. Thus, use this readymade PPT Layout to exemplify blockchain's capacity to enhance trust and reliability in drug traceability.  

Template 10: Drugstore Startup Business Plan

Present a comprehensive business plan detailing a startup’s objectives, strategies, and competitive advantages with this PPT Design. The PPT Template provides placeholders for essential contact details, fostering a sense of accessibility and professionalism. The imagery suggests a focus on community health and personal engagement, which are vital in a healthcare setting. This PPT Slide is thus useful to convey the essence of the business to potential investors, partners, or regulatory bodies, emphasizing customer service and care. Download it today! 

In the end, tackling the drug dilemma is about weaving threads of empathy, knowledge, and resilience into a tapestry of hope. By embracing the stories behind the statistics with pre-designed Drug PowerPoint Templates, we unlock the power to transform despair into healing, guiding each other towards a brighter, more understanding future.

So download your favorites today! 

P.S Launching a new drug is no easy feat. But with a well-defined plan, you can increase your chances of success. How? Give this blog with pharmaceutical product launch templates a read now!

Related posts:

• Top 10 Revenue Cycle Management Templates to Give a Boost to the Healthcare Sector
• Top 10 Templates to Create a Detail-Oriented Web Designer Resume
• Top 10 Rent Contract Template Designs to Sign an Agreement Between Tenant and Landlord
• Top 10 Work Order Proposal Templates With Examples and Samples

Liked this blog? Please recommend us

7 Best Templates for Adopting Artificial Intelligence with Samples and Examples

Top 10 Star Rating Templates with Samples and Examples

This form is protected by reCAPTCHA - the Google Privacy Policy and Terms of Service apply.

Digital revolution powerpoint presentation slides

Sales funnel results presentation layouts

3d men joinning circular jigsaw puzzles ppt graphics icons

Business Strategic Planning Template For Organizations Powerpoint Presentation Slides

Future plan powerpoint template slide

Project Management Team Powerpoint Presentation Slides

Brand marketing powerpoint presentation slides

Launching a new service powerpoint presentation with slides go to market

Agenda powerpoint slide show

Four key metrics donut chart with percentage

Engineering and technology ppt inspiration example introduction continuous process improvement

Meet our team representing in circular format

An official website of the United States government

The .gov means it’s official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

• Publications
• Account settings

Preview improvements coming to the PMC website in October 2024. Learn More or Try it out now .

• Advanced Search
• Journal List
• HHS Author Manuscripts

The Madison Avenue Effect: How drug presentation style influences adherence and outcome in patients with asthma

Emmanuelle m clerisme-beaty.

a Johns Hopkins University, Baltimore MD

Susan J Bartlett

b McGill University, Montreal Canada

W. Gerald Teague

c University of Virginia, Charlottesville VA

d Nemours Children’s Clinic, Jacksonville FL

Charles G Irvin

e University of Vermont, Burlington VE

Rubin Cohen

f Albert Einstein College of Medicine, Bronx NY

Mario Castro

g Washington University, St Louis MO

Robert A Wise

Cynthia s rand.

Little is known about how drug presentation influences medication adherence.

Examine the effect of an educational program aimed at increasing expectations of treatment benefit on medication adherence.

Data are analyzed from 99 participants who underwent electronic drug monitoring during TAPE (Trial of Asthma Patient Education), a randomized placebo-controlled multi-center trial. Participants with suboptimally-controlled asthma were randomized to placebo or montelukast in conjunction with a presentation mode that was either neutral or designed to increase outcome expectancy. Adherence was monitored electronically over 4 weeks, and was defined as ≥ 80% use of prescribed doses. Outcome expectancy, peak expiratory flow, pre-bronchodilator forced expiratory volume, asthma control (ACQ), and asthma-related quality of life were assessed at baseline and at the 4-week follow-up.

Average electronic medication adherence was 69.9%. There was a significant interaction between presentation mode and drug assignment, with participants in the enhanced/montelukast group having a higher change in outcome expectancy (Δ 2.1 points, p < 0.001) and better medication adherence (odds ratio 4.0, CI 1.1, 14.3) compared to those in the neutral/placebo group. There was no difference in asthma symptoms, quality of life, or clinical outcomes based on presentation mode. Rather, increased outcome expectancy was associated with modest improvements in asthma symptoms after adjusting for presentation mode, drug assignment, and medication adherence.

The use of an enhanced presentation aimed at increasing outcome expectancy may lead to improved medication adherence.

Clinical implications

The way treatment is presented to patients may impact their adherence to therapy. Interventions aimed at increasing patients’ expectancy of treatment efficacy may lead to increased medication adherence.

INTRODUCTION

It is well-recognized that adherence to asthma controller therapy is often suboptimal, and that poor adherence can lead to increased asthma-related morbidity and health care expenditures ( 1 – 3 ).

Results from several studies have shown that patient beliefs regarding therapy are predictors of adherence, with negative beliefs and concerns about the safety of therapy associated with decreased medication adherence ( 4 , 5 ). In contrast, positive beliefs about treatment efficacy (i.e., outcomes expectancy) and safety have been shown to be associated with increased adherence ( 6 , 7 , 8 ). As a result, most intervention studies of asthma adherence have included educational components aimed at addressing patients’ beliefs and concerns about therapy ( 9 , 10 ), using methods such as shared decision-making ( 11 ) and motivation-enhancing strategies ( 12 ). We are unaware of any studies that have examined the effect of specifically promoting the benefits of a therapy (i.e., enhancing outcomes expectancy) on medication adherence.

As part of the Trial of Asthma Patient Education (TAPE) ( 13 ), a randomized clinical multicenter trial, we conducted a sub-study electronically monitoring adherence to examine the effect of an educational intervention designed to enhance outcome expectancy on medication adherence. We hypothesized that using an enhanced presentation would lead to more positive outcomes expectancy, which in turn would be associated with higher rates of medication adherence. In addition, the effect of the educational intervention on clinical and patient-reported outcomes was also examined.

Study Design and Organization

This study was carried out as a sub-study of the Trial of Asthma Patient Education, TAPE ( 13 ). Briefly, this is a multi-center randomized clinical trial conducted by the American Lung Association Asthma Clinical Research Centers (ALA-ACRC) to examine the placebo effect in asthma, and to assess whether it could be augmented using an educational program that targeted patients’ expectations of drug efficacy. Participants were enrolled at 19 centers participating in the ALA-ACRC located across the United States. The study was approved by institutional review boards at all participating sites.

The parent study involved four study visits over a 6-week period ( Figure 1 ). After enrollment (Visit 1), there was a 2-week run-in period during which participants were asked to maintain an asthma diary. Baseline data (outcome expectancy, lung function, asthma questionnaires) were collected during Visit 2, and prior to randomization to one of four intervention groups: enhanced/placebo, enhanced/montelukast, neutral/placebo, and neutral/montelukast. After randomization, participants were shown the first educational session and were dispensed the study drug. The educational session was repeated two weeks later during an interim visit with collection of interim pulmonary function and asthma symptom data. Outcome measures (outcome expectancy, lung function, and asthma symptoms) were re-assessed at the end of the study, and unused study drugs were collected.

Study design

Inclusion & Exclusion Criteria

Eligible participants were patients with suboptimally-controlled asthma age 15 years or older who could potentially benefit from use of an additional asthma controller medication. Inclusion criteria were a history of physician diagnosed asthma with regular use of asthma medication in the preceding year; and one or more indicators of poor asthma control. Suboptimal asthma control was defined as an asthma control questionnaire (ACQ) score ≥ 1.5 ( 14 ), use of beta-agonists for asthma symptoms two or more times per week, or nocturnal awakening for asthma one or more times per week. Participants were excluded if they had other serious health problems, were currently using, or had prior intolerance to montelukast.

Drug Assignment

Study tablets were over-encapsulated with gelatin capsules and back-filled with methylcellulose. The active medication treatment was montelukast taken 10 mg orally at bedtime (Singulair, Merck & Co. Whitehouse Station, N.J.). Encapsulation had no effect on the absorption or elimination characteristics of montelukast. The placebos consisted of identical capsules filled with methylcellulose.

Presentation Mode

The educational intervention consisted of an interactive computer-based multimedia presentation about asthma self-care and treatment. The program was given post- randomization after collection of baseline data, and repeated two weeks later at an interim visit. A copy of the presentations can be viewed at the following website: http://www.cctrials.org/Public/TAPE_Patient_Education_Presentation.htm .

The enhanced presentation was designed to increase expectancy regarding the ability of montelukast to adequately control asthma symptoms. Specifically, it included a scripted introduction by a study coordinator, followed by a multimedia presentation embedded with both direct and indirect messages aimed at increasing expectancy of optimal asthma control with use of the medication. As part of the presentation, participants were also shown a consumer-directed television commercial for montelukast to further reinforce the positive message regarding drug efficacy. In contrast, the neutral presentation consisted of a scripted introduction followed by a multi-media presentation with information on asthma care and self-management but without discussion of the benefits of montelukast. An asthma action plan was provided to all participants as part of the study.

Sub-study description

Participants at the five participating centers with electronic adherence monitoring capabilities were enrolled in the sub-study. Electronic monitoring was carried out using Medication Events Monitoring Systems (MEMS) caps (AARDEX Ltd., Zug, Switzerland), which are devices fitted on the study drug bottles to record the date and time of each bottle opening. Adherence was monitored electronically post-randomization over four weeks. In addition, medication adherence was assessed using 2-week recall, daily asthma diaries, and pill count.

Outcome Measures

The primary outcome of interest was adherence based on electronic monitoring. Adherence data were collected post-randomization for four weeks, and truncated at 100% per day, with credit given for one opening per 24-hour period to account for inappropriate use or medication dumping ( 15 ). Mean adherence was calculated as the percent of medication taken as prescribed (actual use/prescribed use *100) over the monitoring period. Good adherence was defined as appropriate use on ≥ 80% of the monitored days based on the MEMS recorded events.

Outcome expectancy was evaluated using two Likert scale questions completed at randomization prior to viewing the multimedia presentation and at completion of the study. Participants were asked to rate their agreement or disagreement with the following items embedded in an asthma perception questionnaire, using a scale of 1 to 9: 1) “If I were to take Singulair (montelukast), it would help my asthma” and 2) “Singulair (montelukast) is likely to help people with asthma”. Outcomes expectancy was analyzed as the sum of the ratings given to the two questions.

Asthma outcomes, including peak expiratory flow (PEF), forced expiratory volume (FEV 1 ), Asthma Control Questionnaire, ACQ ( 16 ), and the Asthma Quality of Life Questionnaire ( 17 ), were obtained at baseline prior to randomization, during the interim visit, and at the end of the study. The ACQ scores range from 0 to 6, with higher scores reflecting poorer asthma control. The Asthma Quality of Life Questionnaire consists of of 15 questions with scores ranging from 1 (severely impaired) to 7 (not at all impaired). The change in FEV 1 , PEF, ACQ and quality of life over the 4-weeks monitoring period was calculated as the difference between Visit 4 and baseline.

Statistical Analysis

Descriptive statistics were calculated using means and standard deviations (SD) for continuous variables, and proportions for categorical variables. Continuous outcome measures were analyzed as changes from baseline values. Statistical analysis of outcomes was performed using one-way ANOVA with Bonferroni adjustment and logistic regression. Models were adjusted for age, gender, ethnicity, education level, drug assignment, the interaction of presentation mode and treatment assignment, and mean adherence as indicated. Based on the sample size of 50 participants per group (enhanced presentation, regular presentation), we had ≥ 80% power to detect a 30% between-group difference in adherence. All analyses were performed based on treatment assignment (intention to treat) using STATA Version 10.0 (StataCorp; College Station, TX).

Participant characteristics

Table 1 shows the baseline characteristics of the four study groups: enhanced/placebo, enhanced/montelukast, neutral/placebo and neutral/montelukast. The majority were white (60.6%) and female (71.7%), with mean (± SD) age of 34.7 ± 14.5 years. Despite imbalances in some baseline characteristics, including the number of females, percentage of participants with higher education and prior asthma-related hospitalization in the enhanced/placebo group compared to the other groups, these were not statistically significant. The groups had other similar baseline characteristics, except for significantly higher baseline peak expiratory flow (PEF) in the enhanced/placebo group.

Baseline characteristics

Values represent Mean (± SD) unless otherwise indicated. PEF= peak expiratory flow; FEV1=forced expiratory volume in 1 second; FVC= forced vital capacity

Effect of presentation mode on outcome expectancy

At baseline, the majority of participants (95%) agreed that montelukast was an effective drug for asthma, with a mean expectancy score (OE) of 12 out of 18 among the groups. At completion of the study, outcome expectancy tended to increase in those participants exposed to active drug, enhanced presentation, or both ( Figure 2 ). The effects of exposure to active drug on OE was additive to that of the enhanced presentation, with the enhanced/montelukast group having the greatest change in OE (Δ 2.7 ±3.0 points), compared to the neutral/placebo group (Δ 0.1±2.8 points).

Change in outcome expectancy score over 4-week treatment period.

Effect of presentation mode on medication adherence

Of the four adherence measures, electronic monitoring had the lowest overall mean adherence with 69.9% of doses taken as prescribed compared to pill count (88.1%), 2-week patient recall (95.2%), and asthma diary (89.7%). Medication adherence was not associated with baseline demographics, except for lower adherence rates in those with a history of acute care utilization in the previous 12 months.

As there was a significant interaction between treatment assignment and presentation mode in predicting adherence, subsequent analyses were stratified by treatment assignment. There was a differential effect of presentation mode on medication adherence depending on whether it was combined with active drug or placebo ( Figure 3 ), with increased adherence (76.0%) when combined with active drug and decreased adherence (26%) when combined with placebo (p < 0.001). There was no difference in adherence to active drug or placebo using the neutral presentation mode (52.0% vs. 47.8% respectively, p = 0.78). Compared to those in the neutral/placebo group, participants in the enhanced/montelukast group had significantly higher adherence rates (OR 4.0, CI 1.1, 14.3), which persisted after adjusting for age, race and gender ( Table 2 ). Although those in the enhanced/placebo group had the lowest adherence rate (26.9%), this was not statistically significant compared to the neutral/placebo group.

Mean adherence rate over four weeks by study condition in participants with asthma.

Odds of adherence to study drug based on study condition.

Effect of presentation mode on asthma outcomes

Presentation mode was not associated with any significant change in any of the asthma outcome measures assessed, including asthma control (p =0.50), asthma quality of life (p= 0.16), FEV 1 (p=0.12), and peak flow (p=0.39). There was an overall trend for improvements in patient reported outcomes over the 4-week treatment period ( Table 3 ), especially in the enhanced/montelukast group. Compared to the neutral/placebo group, the enhanced/montelukast group showed a trend for higher improvements in quality of life (Δ 0.62, CI 0.28, 0.97), along with statistically greater improvements in FEV 1 (Δ 0.15, CI 0.03, 0.26) ( Table 4 ).

Mean change in asthma symptoms and asthma quality of life over four weeks by study condition.

Mean change in selected tests of pulmonary function after four weeks by study condition.

Effect of outcome expectancy on asthma outcomes

Outcome expectancy (OE) was associated with significant improvements in asthma control scores (regression coefficient −0.08, p= 0.004) regardless of age, gender, race, drug assignment or adherence. This effect was clinically modest, however, requiring large changes in outcome expectancy (approximately 7 points) for a meaningful change in asthma control to occur. OE was associated with a trend for modest improvements in asthma quality of life (regression coefficient 0.06, p=0.08), with no statistically significant effect on FEV 1 (p=0.12) or peak expiratory flow (p=0.23).

In this prospective multi-center intervention trial, an enhanced presentation mode designed to influence patients’ outcome expectancy regarding treatment efficacy was associated with improved adherence to taking active drug and FEV 1 , with potentially detrimental effects on adherence to placebo. In addition, increased outcome expectancy was found to be independently associated with improved an asthma control score (ACQ) with a trend for improvements in asthma-specific quality of life. These results suggest that the manner in which medications are introduced to patients may not only affect their expectations about the potential benefits of a therapy, but may also impact their level of adherence.

According to social cognitive theory, an individual’s expectations of a given outcome can act as an incentive (either positive or negative) to influence subsequent behavior ( 18 ). Thus beliefs regarding the outcome of an action/behavior may influence both a person’s motivation and behavior. This theory is well-recognized by advertisers. Marketing messages are effective in promoting sales when the message convinces consumers that they will benefit from buying the product. Similarly, in the present study, we were able to successfully increase outcome expectancy using a multi-media presentation by increasing a patient’s expectations of treatment benefit, with an additive effect of presentation mode and drug assignment on medication adherence.

Few studies have focused on assessing the role of increasing outcome expectancy on medication adherence. A study by Olsen et al. examined the effect of expectancy on adherence to continuous positive airway pressure (CPAP) and found that positive expectancies explained most of the variance in CPAP adherence. ( 19 ). Le et al. found negative beliefs regarding asthma treatment were a significant mediator of the association between minority status and poor adherence ( 20 ). Taken together, these findings suggest that the improved adherence to active drug in response to enhanced presentation may in part be mediated via increased outcome expectancy.

The interaction between outcome expectancy and medication adherence is, however, rather complex. Our study also found that although enhanced presentation was associated with increased adherence and FEV 1 , enhanced expectancy had a negative effect on medication adherence when paired with an ineffective treatment (placebo). This highlights the importance of aligning patients’ expectations with the potential benefits of the treatment. While the reason for the decreased adherence to placebo in the enhanced group is uncertain, we speculate that this finding may be due to a discrepancy between outcome expectancy and drug efficacy, such that failure to notice the expected benefit may have negatively affected adherence. The effect of the enhanced presentation on adherence to placebo was seen within the first week of follow-up, with mean adherence rates of 52% vs. 85% in the enhanced/montelukast group. This difference persisted over the 4-week follow-up, despite a progressive decline in mean adherence over time in all four groups.

We also found outcome expectancy to be associated with improvements in patient reported outcomes (PROs), mainly with regard to asthma control. This effect was independent of drug assignment or medication adherence, suggesting that patient expectations may play a role in perceived benefit, especially as measured by PROs. Patients who believed that their therapies were effective reported health benefits, even when objective measures such as spirometry failed to capture those benefits. This may account for the observed improvements in patient-reported outcome in the enhanced/placebo group. Such observation is consistent with findings from the parent TAPE study, which showed a placebo effect that was augmented using the enhanced presentation mode ( 13 ).

One of the strengths of the present study is the use of electronic monitoring to measure medication adherence objectively. Studies comparing electronic monitoring, pill count, and self report to biological measures of adherence have shown electronic monitoring to be the most valid measure of adherence ( 21 , 22 ). As with other studies, we found that pill counts and self-reports significantly overestimated actual medication use. The current study design is further strengthened by the use of a formalized protocol to increase outcome expectancy which standardized the intervention. The generalizability of our findings is, however, uncertain. Since participants were aware that they would be randomized to placebo or active drug as part of the consent process, the possibility of taking a placebo drug may have influenced their adherence to the therapy. Furthermore, although patients were randomized to the four study groups by center, there were imbalances in baseline demographics which were adjusted for using multiple regression analyses. In addition, the 2-week run-in period may have led to the selection of a very motivated group with higher adherence compared to the general population. However, one would expect such selection bias, if present, to underestimate the effect of the intervention on adherence. It is also unclear whether the observed effect of enhanced presentation on adherence to montelukast would apply to other therapies prescribed to control asthma, such as inhaled corticosteroids, or whether these effects would persist longer than four weeks.

In conclusion, we observed that the manner in which information about an asthma drug was presented to patients significantly influenced their expectations about treatment efficacy and resulted in increased medication adherence to active drug, along with improvements in FEV 1 . Borrowing a lesson from Madison Avenue, we found that marketing the benefits of therapy increased “sales.” In addition, increased outcome expectancy was associated with improvements in patient-reported outcomes, although not objectively measured indices of asthma control. These results suggest that the methods by which treatment options are introduced to patients not only affect adherence to therapy and clinical outcomes, but also impact self-reported outcomes.

Acknowledgments

Declaration of all sources of funding: Supported by grants from National Institutes of Health-National Heart, Lung and Blood Institute grant R01HL073494 and American Lung Association

Abbreviations used

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Effects of Drugs

Jul 29, 2014

170 likes | 809 Views

Effects of Drugs. Alcohol. Alcohol is a depressant that decreases the function of the Central Nervous System. Alcohol can impair coordination, memory, judgment, and decision making Alcohol is both physically and psychologically addictive. Risks and Effects. Short-Term . Long-Term.

Share Presentation

• slurred speech
• central nervous system
• tremors scabs
• highly addictive
• increased blood pressure

Presentation Transcript

Alcohol • Alcohol is a depressant that decreases the function of the Central Nervous System. • Alcohol can impair coordination, memory, judgment, and decision making • Alcohol is both physically and psychologically addictive.

Risks and Effects Short-Term Long-Term Disrupts brain development Liver damage Risk of heart disease Brain cells die Unintentional injuries Family problems • Reduced tension • Poor concentration • Reduced coordination • Slurred speech • Altered emotions • Vomiting • Possible death

Marijuana consists of dried and shredded leaves, seeds, stems and flowers from the plant cannabis sativa. • Marijuana is mainly regarded as a hallucinogenic drug. • Marijuana is a highly psychologically addictive drug. Marijuana

Risks and Effects Short-Term Long-Term Damage to lungs Fatal accidents Depression Anxiety • Distorted perception • Loss of coordination • Trouble with thinking and problem solving • Paranoia and anxiety • Short-term memory loss

Meth is a highly addictive stimulant that releases the brain chemical dopamine. • Meth is a very dangerous drug to make, as it contains many chemicals that are harmful to the body. • Meth can be snorted, smoked, or injected into the bloodstream. Methamphetamine

Risks and Effects Short-Term Long-Term Anxious and violent behavior Tremors Scabs and open sores Loss of weight Prolonged insomnia • Increased wakefulness • Decreased appetite • Irregular heartbeat • Increased blood pressure

Meth: Not Even Once • http://www.youtube.com/watch?v=LkLiwPhdUJU

• More by User

Drugs Their Effects

2 Types of Drug Effects. Therapeutic: Intended effects = GOODNon-therapeutic: Unintended effects = BADMethod of Delivery Matters too:Orally - InhaledIntravenous - Cooked and IngestedSnorted - Other?? method of delivery CHANGES how a drug will affect a person. FYI:

569 views • 27 slides

Harmful Effects of Substance Abuse Drugs

Amphetamines Insomnia Hallucination Racing Heart Cocaine/Crack Infection Stop Breathing Chest pain Ecstasy Vomiting Depression Heart Palpitations GHB Vomiting Breathing Problems Deep Sleep. Heroin Vomiting Diarrhea Infections Inhalants Nosebleeds Loss of hearing

251 views • 22 slides

Drugs &amp; their Effects

Drugs &amp; their Effects. Depressants. Alcohol Barbiturates S olvents and inhalants, like petrol, glue, lighter fluids and paint thinners Benzodiazepines Cannabis Opioids. Alcohol. Short-term effects: Reduces inhibitions, increases feelings of well-being.

479 views • 27 slides

DRUGS AND THEIR EFFECTS

DRUGS AND THEIR EFFECTS. What is a Drug?. A drug is any substance—solid, liquid or gas—that brings about physical and/or psychological changes in the body. What drugs do you think are most commonly used by secondary school students?. 2008 Australian Secondary Students’ Alcohol &amp; Drug Survey.

717 views • 14 slides

Effects of Psychoactive Drugs

Psychoactive drugs affect the central nervous system and can be especially damaging to the developing brain and body of a teen. Effects of Psychoactive Drugs . Psychoactive drugs the functioning of the central nervous system. The effects on a teen’s brain and body can be especially . .

584 views • 36 slides

Effects of Drugs. Cannabis (marijuana, pot, grass, weed). Description: comes from dried tops, leaves, stems and seeds of the marijuana plant

252 views • 11 slides

Types of Drugs and their Effects

Types of Drugs and their Effects. Amphetimines. Strong stimulant drugs that speed up the nervous system “Speed” Examples of amphetamines include methamphetamine, cocaine, and crack. Depressants. Do the opposite of Stimulants

954 views • 12 slides

Effects of Intoxicating Drugs : Party Drugs

Effects of Intoxicating Drugs : Party Drugs. Kayla Carr and Candice Danielson. Ecstasy . nickname for 3,4- methylenedioxymethamphetamine Also called MDMA, Adam, and STP Stimulant and hallucinogen used to improve mood and maintain energy; often used for all-night rave dance parties

259 views • 5 slides

Effects of smoking, drugs and drinking .

Effects of smoking, drugs and drinking. Smoking - a process in which substances (mostly tobacco) are burned and the smoke, which is isolated during this process is inhaled. Effects of smoking. Smoking is very harmful for smoker and people , who stand near him

481 views • 11 slides

Drugs Effects on Our Bodies

Drugs Effects on Our Bodies. ‘ We are stewards of ourselves’. Solvents Alcohol Tobacco. - The effects of these on the health of the body. Aims – To have the information on:. Solvents. Affect behaviour Can damage the lungs, liver and brain. Alcohol. Has an effect on the nervous system

197 views • 9 slides

Effects of drugs on Rabbit blood pressure

Effects of drugs on Rabbit blood pressure. Pharmacological Department Z.G.Song. Questions: Do you know about blood pressure (BP) ?

564 views • 24 slides

Drugs &amp; Their Effects

Drugs &amp; Their Effects. Ms Markowski. Drug Effects &amp; Delivery Methods. Therapeutic: Intended effects = GOOD Non-therap eutic: Unintended effects = S ide Effects 3. 2. 4. 5. Transdermal (skin) Any drug/medicine can be toxic at a certain dose

711 views • 35 slides

Effects of different drugs on isolated intestine

Effects of different drugs on isolated intestine. Experimental purpose. To master the experiment condition of isolated intestinal smooth muscle and effects of different drugs on them;

344 views • 16 slides

DRUGS AND EFFECTS

DRUGS AND EFFECTS. Colorado Springs Police Department Metro Vice, Narcotics and Intelligence Officer Teresa Schutz. / Rev. 2-02. MDMA - Ecstasy. Also known as: XTC X E Pill Roll Clarity Love Drug Hug Drug Disco Biscuits

646 views • 44 slides

Drugs and their effects

Drugs and their effects. A Presentation By. Stephen Hounsom Drug &amp; Alcohol Information &amp; Prevention Officer. STIMULANTS!. Amphetamine. The Effects. Amphetamine is a Stimulant Gives you a intense rush of energy Can last for up to 6hrs Causes loss of appetite

1.17k views • 89 slides

Drugs &amp; Their Effects. Ms Markowski. 2 Types of Drug Effects. Therapeutic: Intended effects = GOOD Non-therapeutic: Unintended effects = BAD Drug Delivery Methods (fast to slow): 1. Smoke/Inhale 4. Orally/Ingest 2. Intravenous 3. Snorted 5.Transdermal

489 views • 35 slides

Effects of drugs on the brain

Drug test fundamentally distinguishes what kind of drugs are inside the individual's body. Please visit http://drugabusecontrol.com/ for more information about drug test. Contact us at (888) 366-5029 or Email us at [email protected] You may follow us: facebook: https://www.facebook.com/drugabusecontrol twitter: https://twitter.com/Drugtestinginc Youtube: https://www.youtube.com/channel/UCmG5iGgdW43Tzz5MH4_6SPQ

314 views • 6 slides

9 Combined effects of drugs.

783 views • 55 slides

THE EFFECTS OF DRUGS ON YOUR CHILDREN

THE EFFECTS OF DRUGS ON YOUR CHILDREN. Sergeant Joseph Hoebeke Hudson Police Department. Class Objectives. Types of Drugs – WHAT WE SEE AS THE MOST COMMON ABUSED DRUGS BY OUR YOUTH Cannabis Type Drugs Prescription Drugs Inhalants Signs and Symptoms of Drug Use (specified categories)

413 views • 38 slides

ILLEGAL DRUGS AND THE EFFECTS

ILLEGAL DRUGS AND THE EFFECTS. TRAVIS LEWIS CLAYTON COUNTY PD. 678-618-3392. ILLEGAL DRUGS AND THE EFFECTS. TITLE INDEX INTRODUCTION WHAT ARE DRUGS? DIFFERENT TYPES OF DRUGS AND EFFECTS. SCHOOL AND DRUGS – YOUTH USAGE STATISTICS. POSITIVE THINGS TO DO TO AVOID DRUG ACTIVITY. CONCLUSION

228 views • 20 slides

The Effects of Drugs on Neurotransmitters

The Effects of Drugs on Neurotransmitters. Agonist - mimic OR increase Nts’effects Antagonist - block the Nts’ effects Can facilitate OR inhibit production and release of Nts Can alter Nt’s effects after attachment to receptors. Other Examples:. Cocaine : affects dopamine system

109 views • 9 slides

The Visual Effects of Drugs over time

The Visual Effects of Drugs over time. This is a series of arrest photographs of the same individual taken over the course of 10 years that graphically shows the changes to the human body.

50 views • 4 slides